Literature DB >> 18686

On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use.

S Björkman, H Sievertsson.   

Abstract

Pro-Leu-Gly-NH2 (MIF) inhibits the tremor induced by oxotremorine. Objective measurement of this tremor permits the drawing of a dose-effect curve. The inhibitory effect of the peptide increases linearly with increasing doses until an optimum is reached (between 30 and 40 mg/kg i.p.). At still higher doses the peptide is inactive. The same phenomenon is observed with analogues of MIF. This finding may have important bearings on the interpretation of clinical and experimental data obtained with MIF.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 18686     DOI: 10.1007/BF00508614

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  15 in total

1.  Peptides related to melanostatin (Pro-Leu-Gly-NH2) as inhibitors of oxotremorine-induced tremor.

Authors:  S Björkman; S Castensson; B Lindeke; H Sievertsson
Journal:  Acta Pharm Suec       Date:  1976

2.  Double-blind evaluation of oral L-prolyl-Lleucyl-glycine amide in Parkinson's disease.

Authors:  A Barbeau; M Roy; A J Kastin
Journal:  Can Med Assoc J       Date:  1976-01-24       Impact factor: 8.262

3.  Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.

Authors:  A J Kastin; A Barbeau
Journal:  Can Med Assoc J       Date:  1972-12-09       Impact factor: 8.262

4.  Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone release-inhibiting factor, thyrotropin releasing hormone and related peptides.

Authors:  S Castensson; H Sievertsson; B Lindeke; C Y Sum
Journal:  FEBS Lett       Date:  1974-08-15       Impact factor: 4.124

5.  DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF).

Authors:  N P Plotnikoff; A J Kastin; M S Anderson; A V Schally
Journal:  Life Sci I       Date:  1971-11-15

6.  Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II.

Authors:  J P Huidobro-Toro; A Scotti de Carolis; V G Longo
Journal:  Pharmacol Biochem Behav       Date:  1975 Mar-Apr       Impact factor: 3.533

7.  Oxotremorine antagonism by a hypothalamic hormone, melanocyte-stimulating hormone release-inhibiting factor (MIF).

Authors:  N P Plotnikoff; A J Kastin; M S Anderson; A V Schally
Journal:  Proc Soc Exp Biol Med       Date:  1972-07

8.  Deserpidine antagonism by a tripeptide, L-prolyl-L-leucyglycinamide.

Authors:  N P Plotnikoff; A J Kastin; M S Anderson; A V Schally
Journal:  Neuroendocrinology       Date:  1973       Impact factor: 4.914

9.  Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrom.

Authors:  P A Fischer; E Schneider; P Jacobi; H Maxion
Journal:  Eur Neurol       Date:  1974       Impact factor: 1.710

10.  [Infusion therapy with mif (melanocyte inhibiting factor) in Parkinson's disease (author's transl)].

Authors:  F Gerstenbrand; H Binder; C Kozma; S T Pusch; T h Reisner
Journal:  Wien Klin Wochenschr       Date:  1975-12-26       Impact factor: 1.704

View more
  3 in total

1.  Behavioural effects of naloxone in rats.

Authors:  A Bertolini; S Genedani; M Castelli
Journal:  Experientia       Date:  1978-06-15

2.  Acoustic biosensors for ultrasound imaging of enzyme activity.

Authors:  Anupama Lakshmanan; Zhiyang Jin; Suchita P Nety; Daniel P Sawyer; Audrey Lee-Gosselin; Dina Malounda; Mararet B Swift; David Maresca; Mikhail G Shapiro
Journal:  Nat Chem Biol       Date:  2020-07-13       Impact factor: 15.040

3.  Lambda Red-Mediated Recombination in Shiga Toxin-Producing Escherichia coli.

Authors:  Kenneth G Campellone; Alyssa M Coulter
Journal:  Methods Mol Biol       Date:  2021
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.